Oncotarget

Research Papers:

AKT mediates actinomycin D-induced p53 expression

Chih-Shou Chen, Dong-Ru Ho, Fei-Yun Chen, Chang-Rong Chen, Yu-De Ke and Jyan-Gwo J Su _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:693-703. https://doi.org/10.18632/oncotarget.1328

Metrics: PDF 2535 views  |   HTML 2833 views  |   ?  


Abstract

Chih-Shou Chen1, Dong-Ru Ho1, Fei-Yun Chen2, Chang-Rong Chen2, Yu-De Ke2, Jyan-Gwo Joseph Su2

1 Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, ROC

2 Department of Biochemical Science and Technology, National Chiayi University, Chiayi 600, Taiwan, ROC

Correspondence:

Jyan-Gwo Joseph Su, email:

Keywords: Actinomycin D, AKT, p53

Received: August 28, 2013 Accepted: January 11, 2014 Published: January 11, 2014

Abstract

At high cytotoxic concentrations, actinomycin D (ActD) blocks transcription, decreasing levels of MDM2 and thus causing p53 stabilization. At low cytostatic concentrations, ActD causes ribosomal stress, which decreases MDM2 activity, resulting in p53 stabilization and activation. ActD can thus be used for p53-based cyclotherapy. We analyzed pathways mediating ActD-induced p53 expression. Inhibitors (LY294002, wortmannin, and deguelin) of phosphatidylinositol 3-kinases (PI3K) and AKT, but not inhibitors of MEK1/2, JNK, and p38-MAPK abolished the ActD-induced p53 expression in diverse cell types. RNA interference further supported these results. When AKT was downregulated by small hairpin RNA-AKTs, ActD-induced p53 expression was significantly decreased. ActD caused AKT phosphorylation at Ser473, indicating full activation of AKT. The potential for cancer therapy is discussed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1328